HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $75.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential downside of 31.70% from the company’s previous close.

Several other brokerages have also recently issued reports on SRPT. Guggenheim increased their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Robert W. Baird cut their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a research report on Tuesday. They issued a “hold” rating and a $136.00 price target for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $176.77.

Sarepta Therapeutics Trading Up 0.1 %

Shares of SRPT opened at $109.81 on Thursday. The firm has a market capitalization of $10.49 billion, a price-to-earnings ratio of 87.85 and a beta of 0.75. The company has a 50-day moving average of $120.16 and a 200 day moving average of $125.22. Sarepta Therapeutics has a 1-year low of $102.15 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock valued at $1,104,701,000 after purchasing an additional 117,904 shares during the period. Janus Henderson Group PLC raised its stake in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after buying an additional 543,143 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares during the period. Geode Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock worth $207,538,000 after buying an additional 9,999 shares during the last quarter. Finally, Norges Bank acquired a new stake in Sarepta Therapeutics during the fourth quarter worth about $126,315,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.